In vivo molecular imaging in Parkinson’s disease

Parkinson's Disease, Second Edition

Volumn , Issue , 2012, Pages 787-801

  Sharma, Sushil K ^a   Ebadi, Manuchair ^b,c  

^a Department of Pharmacology ^*  (Netherlands)

^b Cyclotron and Positron Emission Tomography Imaging Research Laboratory   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055818492     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12948     Document Type: Chapter

References (81)

1. Gerlach M, Hendrich A, Hueber R, Jost W, Winkler J, Woitalla D, and Riederer P. Early detection of Parkinson’s disease: Unmet needs. Neurodegener Dis. 2008; 5: 137-139.
2. Berg D. Marker for a preclinical diagnosis of Parkinson’s disease as a basis for neuroprotection. J Neural Transm Suppl. 2006; 71: 123-132.
3. Meltzer CC. Neuropharmacology and receptor studies in the elderly. Rev Neurol. 2002; 35: 767-777.
4. Rueger MA, Kracht LW, Hilker R, Theil A, Sobosky J, Winkeler A, Thomas AV et al. Role of in vivo imaging of the central nervous system for developing novel drugs. Q J Nucl Med Mol Imaging. 2007; 51: 164-181.
5. Bohnen NI and Frey KA. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol. 2007; 9: 243-257.
6. Leenders KI and Oertel WH. Parkinson’s disease: Clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. Neural Plast. 2001; 8: 99-110.
7. Ransmayr G. Clinical criteria of Parkinson’s disease. Ther Umsch. 2007; 64: 5-8.
8. Small GW. Neuroimaging as a diagnostic tool in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2004; 17: 25-31.
9. Water CH, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ, Nygaard TG, Moskowitz CB, Fahn S, and Calne DB. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women. Neurology. 1993; 43: 1555-1558.
10. Brooks DJ. The early diagnosis of Parkinson’s disease. Ann Neurol. 1998; 44: S10-S18.
11. Hattori N, Shimura H, Kubo S, Kitada T, Wang M, Asakawa S, Minashima S, Suzuki T, Tanaka K, and Mizuno Y. Autosomal recessive juvenile parkinsonism: A key to understanding nigral degeneration in sporadic Parkinson’s disease. Neuropathology. 2000; 20 Suppl: S85-S90.
12. Khan NL, Valent EL, Bentivigolio AR, and Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An 18F-dopa PET study. Ann Neurol. 2002; 52: 849-853.
13. Lin CH, Tzen KY, Yu CY, Tai CH, Farrer MJ, and Wu RM. LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: Clinical, PET, and functional studies. J Biomed Sci. 2008; 15: 661-667.
14. Koller WC. When does Parkinson’s disease begin? Neurology. 1992; 42: 27-31.
15. Jenner P. Presymptomatic detection of Parkinson’s disease. J Neural Transm Suppl. 1993; 40: 23-36.
16. Ishikawa T, Dhawan V, Chaly T, Margouleff C, Robeson W, Dahl JR, Mandel F, Spetsieris P, and Eidelberg D. Clinical significance of striatal DOPA decarboxylase activity in Parkinson’s disease. J Nucl Med. 1996; 37: 216-222.
17. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, and Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996; 40: 873-874.
18. Momose T and Sasaki Y. Striatal dopamine D2 receptor in Parkinson disease and its related disorders assessed by C-11 NMSP and PET. Nippon Rinsho.1997; 55: 227-232.
19. Brownell AL, Jenkins BG, and Isacson O. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson’s disease. Biomed Pharmacother. 1999; 53: 131-140.
20. Shintoh H. PET study of cholinergic system in the brain. Rinsho Shinkeigaku. 1999; 39: 33-35.
21. Matsuda H. SPECT and PET in Parkinson’s disease. Nippon Rinsho. 2000; 58: 2000-2006.
22. Cicchetti F, Brownell AL, Williams K, Chen YI, Levni E, and Issacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002; 15: 991-998.
23. Holloway RG and Dick AW. Clinical trial end points: On the road to nowhere? Neurology. 2002; 58: 679-686.
24. Brooks DJ, Frey KA, Marek KI, Oakes D, Paty D, Prentice R, Suhlts CW, and Stoessl AJ. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Exp Neurol. 2003; 184 Suppl 1: S68-S79.
25. Goldstein DL, Holmes C, Sharabi Y, Brentzel C, and Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology. 2003; 60: 1327-1332
26. Huang CC. Parkinsonism induced by chronic manganese intoxication-An experience in Taiwan. Chang Gung Med J. 2007; 30: 385-395.
27. Waterhouse RN and Zhao J. In vivo tomographic imaging studies of neurodegeneration and neuroprotection: A review. Method Mol Biol. 2007; 399: 215-223.
28. Schwarz J, Gartz S, Hahn U, Forstl H, and Jarnig M. The status of imaging methods for the treatment of patients with Parkinson’s syndrome. Dtsch Med Wochenschr. 2008; 113: S8-S10.
29. Lorenzp-Boaquet C, Hernandez-Vera J, Castell-Conesa J, and Miguel-Rodriquez F. Functional neuroimaging with SPECT in Parkinson’s disease and Parkinsonisms. Rev Neurol. 2008; 46: 430-435.
30. Nandahgopal R, Mckeown MJ, and Stoessl AJ. Functional imaging in Parkinson disease. Neurology. 2008; 70: 1478-1488.
31. Davis PC, Mirra SS, and Alazraki N. The brain in older persons with and without dementia: Findings on MR, PET, and SPECT images. AJR Am J Roentgenol. 1994; 162: 1267-1278.
32. Sawel GV. The detection of preclinical Parkinson’s disease: What is the role of positron emission tomography? Mov Disord. 1995; 8: 271-277.
33. Berg D, Roggendorff W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O et al. Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002; 59: 999-1005.
34. Forstl H, Gratz S, Hahn U, Schwarz J, and Jarnig M. Dementia with Lewy bodies and reduced dopamine transporter binding indicates significant acetylcholine deficiency. Dtsch Med Wochenschr. 2008; 113S: S11-S14.
35. Suhara T and Miyoshi M. Distribution and function of dopamine D1, D2 receptor. Rinsho Shinkeigaku. 2007; 47: 826-828.
36. Berk M, Doss S, Kauer-Santanma M, Malhi GS, Bourin M, Kapzinski F, and Norman T. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl. 2007; 434: 41-49.
37. Kumar JS and Mann JJ. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov Today. 2007; 12: 748-756.
38. Bartels AL and Leenders KL. Neuroinflammation in the pathophysiology of Parkinson’s disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord. 2007; 22: 1852-1856.
39. Szczudlik A, Rudinska M. Neuroprotective effect of dopamine agonists. Neurol Neurochir Pol. 2007; 41: S22-S28.
40. Schiffer WK, Liebling CN, Patel V, and Dewsey SL. Targeting the treatment of drug abuse with molecular imaging. Nucl Med Biol. 2007; 34: 833-847.
41. Wong DF, Gunder G, and Brasic J. Brain imaging research: Does the science serve clinical practice? Int Rev Psychiatry. 2007; 19: 541-548.
42. Gartz S, Hahn U, Kaiser JW, Jarnig M, Schwarz J, and Forstl H. Nuclear medicine imaging in neurodegenerative dementias. Dtsch Med Wochenschr. 2008; 133: S5-S7.
43. Seibyl JP, Chen W, and Silverman JP. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med. 2007; 37: 440-450.
44. Mathonnett M. Gastrointestinal carcinoid tumors: A multi-technique diagnostic approach. J Chir (Paris). 2007; 144: 287-292.
45. Yu Y and Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn. 2007; 7: 659-672.
46. Hughes AJ, Daniel SE, Blankson S, and Lees AJ. A clinicopathological study of 100 cases of Parkinson’s disease. Arch Neurol. 1993; 50: 140-148.
47. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord. 2003; 18 Suppl 7: S63-S70.
48. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001; 220: 373-380.
49. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, Feigin A, and Eidelberg D. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008; 23: 727-733.
50. Berg D. Transcranial sonography in the early and differential diagnosis of Parkinson’s disease. J Neural Transm Suppl. 2006; 70: 249-254.
51. Kumakura Y, Danielson EH, Reilhac A, Gjedde A, Cumming P. Levodopa effect on [18F]fluorodopa influx to brain: Normal volunteers and patients with Parkinson’s disease. Acta Neurol Scand. 2004; 110: 188-195.
52. Szczudlick A and Rubinska M. Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson’s disease? Yes. Neurol Neurochir Pol. 2007 41(2 Suppl 1): S6-S9.
53. Mendez I, Sanchez-Permaute R, Cooper O, Vinuela A, Ferrari D, Bjorklund L, Dagher A, and Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease. Brain. 2005; 128: 1498-1510.
54. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan D, During MJ, and Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease. Proc Natl Acad Sci USA. 2007; 104: 19559-19564.
55. Seibyl J, Jennings D, Tabamo R, and Marek K. Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson’s disease research. Q J Nucl Med Mol Imaging. 2005; 49: 215-221.
56. Sharma S and Ebadi M. Therapeutic potential of metallothioneins in Parkinson’s disease. In New Research on Parkinson’s Disease, Eds. Timothy F. Hahn and Julian Werner. Nova Science Publishers, New York, Chapter 1, 2008, pp. 1-41.
57. Ravina B, Eidelberg D, Ahlskog JE, Albin RI, Brooks DI. The role of radiotracer imaging in Parkinson disease. Neurology. 2005; 64: 208-215.
58. Kung HF, Kung MP, Wev SP, Lin KJ, and Yen TC. Clinical acceptance of a molecular imaging agent: A long march with [99mTc]TRODAT. Nucl Med Biol. 2007; 34: 787-789.
59. Bohnen NI, Kuwabara H, Constanine GM, Mathis CA, and Moore RY. Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson’s disease. Neurosci Lett. 2007; 424: 185-189.
60. Sharma S and Ebadi M. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative and nitrative stress in dopaminergic neurons. Antioxid Redox Signal. 2003; 5: 251-264.
61. Ebadi M and Sharma S. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease. Antioxid Rexdox Signal. 2003; 5: 319-335.
62. Sharma S, Kheradpezhou M, Shavali S, El Refaey H, Eken J, Hagen C, and Ebadi M. Neuroprotective actions of coenzyme Q10 in Parkinson’s disease. Methods Enzymol. 2004; 382: 488-509.
63. Ebadi M, Brown-Borg H, Garrett S, Singh B, Shavali S, and Sharma S. Metallothioneins-mediated neuroprotection in genetically-engineered mouse models of Parkinson’s disease and Aging. Mol Brain Res. 2005a; 134: 67-75.
64. Sharma S, Refaey HE, and Ebadi M. Complex-1 activity and 18F-DOPA uptake in genetically-engineered mouse models of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Res. Bull. 2006; 70: 22-32.
65. Sharma S, Calson E, and Ebadi M. The neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium (MPP+)-induced apoptosis in dopaminergic neurons. J Neurocytol. 2003; 32: 329-343.
66. Bollimnutha S, Singh B., Shavali S, Sharma S, and Ebadi M. TRPC-1-mediated inhibition of MPP+ toxicity in human SH-S-Y5Y neuroblastoma cells. J Biol Chem. 2005; 280: 2132-2140.
67. Ebadi M and Sharma S. Metallothioneins isoforms attenuate peroxynitrite-induced oxidative stress in Parkinson’s disease. J Exp Biol Med. 2006a; 231: 1576-1583.
68. Ebadi M and Sharma S. Vitamin E and coenzyme Q10 in Parkinson’s disease. In The Encyclopedia of Vitamin E, Eds. V.R. Preedy and R.R. Watson. CAB International, Wallingford, U.K., 2006b.
69. Sharma S and Ebadi M. An improved method for analyzing coenzyme Q homologues and multiple detection of rare biological samples. J Neurosci Methods. 2004; 137: 1-8.
70. Sharma S and Ebadi M. Distribution kinetics of 18F-DOPA in weaver mutant mice. Mol Brain Res. 2005; 139: 23-30.
71. Sharma S and Ebadi M. SPECT Neuroimaging in translational research of CNS disorders. Neurochem Int. 2008; 52: 352-362.
72. Ebadi M, Sharma S, Ghafourifar P, Brown-Borg H, and Refaey HE. Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role of metallothioneins. Methods Enzymol. 2005b; 396: 276-298.
73. Ebadi M, Sharma S, Wanpen S, and Amornpan A. Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation. J Cell Mol Med. 2004; 8: 213-222.
74. Ebadi M, Wanpen S, Shavali S, and Sharma S. Coenzyme Q10 stabilizes mitochondria in Parkinson’s disease. In Molecular Interventions in Lifestyle-Related Diseases, Ed. M. Hiramatsu. Marcel Dekker, New York, 2005c, pp. 127-153.
75. Ma Y, Tang C, Spetsieris PG, Dhawan V, and Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: Test-retest reproducibility. J Cereb Blood Flow Metab. 2007; 27: 597-605.
76. Nagai Y, Obayashi S, Ando K, Inaji M, Maeda J, Okauchi T, Ito H, and Suhara T. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse. 2007; 61: 809-819.
77. Nikolaus S, Antke C, Kley K, Poeppel TD, Hautzel H, Schmidt D, and Muller HW. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci. 2007; 18: 439-472.
78. Nikolaus S, Larisch R, Beu M, Antke C, Kley K, Forutan F, Wirrwar A, and Muller HW. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev Neurosci. 2007; 18: 473-504.
79. Sharma S, Krause G, and Ebadi M. Basic requirements of quality control of PET radiopharmaceuticals. Proceeding of the International Atomic Energy Agency, Bangkok, Thailand, November 10-14, 2007.
80. Sharma SK, El Refaey H, and Ebadi M. Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res. 2006; 31: 303-311.
81. Sharma S, Krause G, and Ebadi M. Radiation safety and quality control in the cyclotron laboratory. Radiat Prot Dosimetry. 2006; 118: 431-439.